STOCK TITAN

Avalo Therapeutics (AVTX) SEC Filings, Aug-Nov 2026

AVTX NASDAQ

Avalo Therapeutics, Inc. filings document clinical, financial, capital-structure, and governance disclosures for a biotechnology issuer developing IL-1β-based therapies. Recent 8-K reports cover abdakibart LOTUS trial materials in hidradenitis suppurativa, operating and financial results, investor presentation updates, and material agreements related to milestone obligations from the AlmataBio acquisition.

The company's proxy materials describe shareholder voting matters, board composition, executive compensation, equity awards, and governance practices. Avalo's filing record also includes disclosure categories tied to common stock and pre-funded warrant financing, Nasdaq inducement awards, risk and operating updates, and formal reporting of material events affecting its clinical-stage business.

Rhea-AI Summary

Avalo Therapeutics, Inc. (AVTX) reported a net loss of $18.945 million for the three months ended September 30, 2026, compared with $30.625 million a year earlier; nine-month net loss was $74.933 million versus $64.539 million. Net cash used in operating activities for the nine months was $49.220 million, compared with $37.212 million in 2025. At September 30, cash, cash equivalents and investments totaled $462.8 million; management expects these resources to fund operations into 2029 under current operating plans.

On May 7, 2026, Avalo completed a follow-on offering of common stock and pre-funded warrants, reporting net proceeds of $404.9 million. Common shares issued and outstanding totaled 53,923,083 at September 30; common shares outstanding were 57,823,083 as of November 2, 2026. The company settled its amended AlmataBio milestone arrangement in the second quarter, issuing 128,189 common shares; no contingent milestone obligations remain from that transaction.

Nine-month research and development expense was $52.512 million, including a $10.0 million milestone expense payable to Eli Lilly upon dosing a patient in an abdakibart Phase 3 trial; Avalo considered achievement probable and accrued the amount at September 30. Avalo is a clinical-stage biotechnology company advancing abdakibart into a Phase 3 registrational program for hidradenitis suppurativa and developing AVTX-010.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.22%
Tags
quarterly report
-
Rhea-AI Summary

Avalo Therapeutics, Inc. common stock is the subject of a Schedule 13G reporting that Trails Edge Biotechnology Master Fund, LP beneficially owned 2,803,761 shares, or 5.2%, as of October 22, 2026. The shares are held directly by the Master Fund; its investment manager, Trails Edge Capital Partners, LP, and Ortav Yehudai, Chief Investment Officer of Trails Edge Capital, may also be deemed to beneficially own those same shares. The 5.2% calculation is based on 53,629,989 shares issued and outstanding as of August 3, 2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.63%
Tags
ownership
-
Rhea-AI Summary

Avalo Therapeutics, Inc. director Rita Jain received a grant of 1,322 stock options on September 30, 2026. The options were 100% vested and were issued under the Amended and Restated Non-Employee Director Compensation Plan in lieu of Board fees. The report lists a transaction price of $12.29 per share and an exercise price of $15.33 per share. The options expire September 30, 2036, and Jain's reported position after the transaction was 1,322 options.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.60%
Tags
insider
Rhea-AI Summary

Avalo Therapeutics, Inc. director Kevin Robert Lind received 1,352 stock options on September 30, 2026. The award was 100% vested and was issued under the Amended and Restated Non-Employee Director Compensation Plan in lieu of Board fees. Lind's reported post-transaction option position was 1,352.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.60%
Tags
insider
-
Rhea-AI Summary

Avalo Therapeutics, Inc. (AVTX) director Ron M. Philip received 1,109 stock options on September 30, 2026. The options were 100% vested, carry a $15.33 exercise price, and expire September 30, 2036. They were granted under the Amended and Restated Non-Employee Director Compensation Plan in lieu of Board fees.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.60%
Tags
insider
-
Rhea-AI Summary

Avalo Therapeutics, Inc. (AVTX) reported that Chief Financial Officer Christopher Ryan Sullivan exercised stock options for 12,394 shares of common stock on September 16, 2026 at an exercise price of $9.88 per share and sold the same number of shares at a weighted-average price of $16.33 per share. The transactions were carried out under a Rule 10b5-1 trading plan adopted on May 18, 2026. Following the option exercise, Sullivan held 83,848 options to purchase additional shares of Avalo Therapeutics common stock.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.41%
Tags
insider
Rhea-AI Summary

Avalo Therapeutics, Inc. (AVTX) reported that Chief Financial Officer Christopher Ryan Sullivan exercised stock options for 10,185 shares of common stock at an exercise price of $8.04 per share on September 10, 2026, then sold 10,185 shares of common stock at a weighted average price of $17.6197 per share in multiple transactions. These trades were effected pursuant to a Rule 10b5-1 trading plan adopted on May 18, 2026. Following the option exercise, he continued to hold 105,815 options to purchase common stock at $8.04 per share, expiring on January 28, 2035, with the option vesting 25% on January 28, 2026 and the balance in equal monthly installments over the following three years, subject to continued service.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.37%
Tags
insider
-
Rhea-AI Summary

Avalo Therapeutics, Inc. (AVTX) reported that Chief Medical Officer Mittie Doyle exercised stock options for 679 shares of common stock at an exercise price of $8.04 per share and on the same day sold 679 shares of common stock at $20.00 per share. After the option exercise, Doyle held 113,734 stock options directly. All transactions were effected under a Rule 10b5-1 trading plan adopted on November 13, 2025, and the underlying option grant vests 25% on January 28, 2026, with the remainder vesting in equal monthly installments over the following three years.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.06%
Tags
insider
-
Rhea-AI Summary

Avalo Therapeutics, Inc. (AVTX) reported that its Chief Financial Officer, Christopher Ryan Sullivan, exercised stock options and sold common shares in mid-August 2026. He exercised options to acquire a total of 71,852 shares of common stock at an exercise price of $9.88 per share on August 17 and 18, 2026. Over the same two days, he sold 72,725 shares of common stock in open-market transactions at per-share prices reported around $19.85–$20.05, with specific trades occurring within disclosed ranges. The options exercised were part of grants expiring in 2034 and vesting 25% on March 28, 2025 and monthly thereafter. All transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on May 18, 2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.48%
Tags
insider
Rhea-AI Summary

Avalo Therapeutics, Inc. (AVTX) reported insider transactions by Chief Medical Officer Mittie Doyle. On August 17, 2026, Doyle exercised options to acquire 1,000 shares of common stock at $12.65 per share and sold 1,000 shares at $20.00 per share, pursuant to a Rule 10b5-1 trading plan adopted on November 13, 2025. Following the option exercise, Doyle directly owned 123,750 shares of common stock.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.48%
Tags
insider

FAQ

How many Avalo Therapeutics (AVTX) SEC filings are available on StockTitan?

StockTitan tracks 184 SEC filings for Avalo Therapeutics (AVTX), including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and Form 4 insider trading disclosures. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.

When was the most recent SEC filing for Avalo Therapeutics (AVTX)?

The most recent SEC filing for Avalo Therapeutics (AVTX) was filed on November 16, 2026.